346 related articles for article (PubMed ID: 28435907)
21. Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design.
Diaz-Cano SJ
Int J Mol Sci; 2012; 13(2):1951-2011. PubMed ID: 22408433
[TBL] [Abstract][Full Text] [Related]
22. Evolutionary perspectives, heterogeneity and ovarian cancer: a complicated tale from past to present.
Achimas-Cadariu P; Kubelac P; Irimie A; Berindan-Neagoe I; Rühli F
J Ovarian Res; 2022 Jun; 15(1):67. PubMed ID: 35659345
[TBL] [Abstract][Full Text] [Related]
23. Navigating the challenge of tumor heterogeneity in cancer therapy.
Fedele C; Tothill RW; McArthur GA
Cancer Discov; 2014 Feb; 4(2):146-8. PubMed ID: 24501303
[TBL] [Abstract][Full Text] [Related]
24. Cancer's second genome: Microbial cancer diagnostics and redefining clonal evolution as a multispecies process: Humans and their tumors are not aseptic, and the multispecies nature of cancer modulates clinical care and clonal evolution: Humans and their tumors are not aseptic, and the multispecies nature of cancer modulates clinical care and clonal evolution.
Sepich-Poore GD; Guccione C; Laplane L; Pradeu T; Curtius K; Knight R
Bioessays; 2022 May; 44(5):e2100252. PubMed ID: 35253252
[TBL] [Abstract][Full Text] [Related]
25. Tumour heterogeneity and immune-modulation.
Jamal-Hanjani M; Thanopoulou E; Peggs KS; Quezada SA; Swanton C
Curr Opin Pharmacol; 2013 Aug; 13(4):497-503. PubMed ID: 23664091
[TBL] [Abstract][Full Text] [Related]
26. Genetic and epigenetic determinants of B-cell lymphoma evolution.
Izzo F; Landau DA
Curr Opin Hematol; 2016 Jul; 23(4):392-401. PubMed ID: 27135978
[TBL] [Abstract][Full Text] [Related]
27. Clonal evolution and tumor-initiating cells: New dimensions in cancer patient treatment.
Apostoli AJ; Ailles L
Crit Rev Clin Lab Sci; 2016; 53(1):40-51. PubMed ID: 26397062
[TBL] [Abstract][Full Text] [Related]
28. Evolutionary dynamics of intratumor heterogeneity.
Iwasa Y; Michor F
PLoS One; 2011 Mar; 6(3):e17866. PubMed ID: 21479218
[TBL] [Abstract][Full Text] [Related]
29. Adapting clinical paradigms to the challenges of cancer clonal evolution.
Murugaesu N; Chew SK; Swanton C
Am J Pathol; 2013 Jun; 182(6):1962-71. PubMed ID: 23708210
[TBL] [Abstract][Full Text] [Related]
30. Tumour heterogeneity and resistance to cancer therapies.
Dagogo-Jack I; Shaw AT
Nat Rev Clin Oncol; 2018 Feb; 15(2):81-94. PubMed ID: 29115304
[TBL] [Abstract][Full Text] [Related]
31. Mathematical modeling in cancer drug discovery.
Wang Z; Deisboeck TS
Drug Discov Today; 2014 Feb; 19(2):145-50. PubMed ID: 23831857
[TBL] [Abstract][Full Text] [Related]
32. Multiregion Sequence Analysis to Predict Intratumor Heterogeneity and Clonal Evolution.
Ahn S; Huang H
Methods Mol Biol; 2021; 2243():283-296. PubMed ID: 33606263
[TBL] [Abstract][Full Text] [Related]
33. Cancer in light of experimental evolution.
Sprouffske K; Merlo LM; Gerrish PJ; Maley CC; Sniegowski PD
Curr Biol; 2012 Sep; 22(17):R762-71. PubMed ID: 22975007
[TBL] [Abstract][Full Text] [Related]
34. A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration.
Schürch CM; Rasche L; Frauenfeld L; Weinhold N; Fend F
Virchows Arch; 2020 Mar; 476(3):337-351. PubMed ID: 31848687
[TBL] [Abstract][Full Text] [Related]
35. Clonal evolution and expansion associated with therapy resistance and relapse of colorectal cancer.
S A; Chakraborty A; Patnaik S
Mutat Res Rev Mutat Res; 2022; 790():108445. PubMed ID: 36371022
[TBL] [Abstract][Full Text] [Related]
36. Long range personalized cancer treatment strategies incorporating evolutionary dynamics.
Yeang CH; Beckman RA
Biol Direct; 2016 Oct; 11(1):56. PubMed ID: 27770811
[TBL] [Abstract][Full Text] [Related]
37. Capturing Tumor Heterogeneity and Clonal Evolution by Circulating Tumor DNA Profiling.
Scherer F
Recent Results Cancer Res; 2020; 215():213-230. PubMed ID: 31605231
[TBL] [Abstract][Full Text] [Related]
38. Multiscale heterogeneity in gastric adenocarcinoma evolution is an obstacle to precision medicine.
Röcken C; Amallraja A; Halske C; Opasic L; Traulsen A; Behrens HM; Krüger S; Liu A; Haag J; Egberts JH; Rosenstiel P; Meißner T
Genome Med; 2021 Nov; 13(1):177. PubMed ID: 34749812
[TBL] [Abstract][Full Text] [Related]
39. Re-Evaluating Clonal Dominance in Cancer Evolution.
Burrell RA; Swanton C
Trends Cancer; 2016 May; 2(5):263-276. PubMed ID: 28741512
[TBL] [Abstract][Full Text] [Related]
40. Cancer evolution: mathematical models and computational inference.
Beerenwinkel N; Schwarz RF; Gerstung M; Markowetz F
Syst Biol; 2015 Jan; 64(1):e1-25. PubMed ID: 25293804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
